

鹿児島医療センター英文論文一覧（2026）

NEW !

切除された爪メラノーマに対する補助療法としてのインターフェロン β と経過観察の有効性：多施設共同後向き研究

Komori T, Nakano E, Kiniwa Y, Mori S, Yamamoto S, Kato H, Yoshikawa S, Yoshino K, **Aoki M**, Takenouchi T, Maeda T, Yoshino K, Ohe S, Nakama K, Ishikawa H, Nakamura Y, Takai T, Ito T, Kitagawa H, Kokubu H, Hatta N, Funakoshi T, Hoashi T, Suyama T, Fujiwara S, Masuzawa M, Uchi H, Miyagawa T, Kado S, Yamamoto Y, Asai J, Kato J, Maeda T, Baba N, Kato Y, Oashi K, Maekawa T, Jinnai S, Nishizawa A, Kagoyama K, Otsuka A, Nishihara K, Ogata D, Namikawa K, Nakamura Y, **Matsushita S**.

Efficacy of Adjuvant Interferon- β Versus Observation for Resected Nail Apparatus Melanoma: A Multicenter Retrospective Study.

The Journal of Dermatology. 2026 Jul; 0: 1–9

Journal Impact Factor 2025: 2.8

PMID: PMID: [42410902](https://pubmed.ncbi.nlm.nih.gov/42410902/) doi: <https://doi.org/10.1111/1346-8138.70375>

センチネルリンパ節転移を伴う足底の末端メラノーマ患者における、即時完全リンパ節郭清術と経過観察の予後転帰：多施設共同後向き研究

Inoue S, Koizumi S, Yamazaki N, Ichigozaki Y, Kitagawa H, Kiniwa Y, Sato S, Takai T, Doi R, Ito T, Yasuda M, Kuwatsuka Y, Maekawa T, Asai J, Miyagawa T, **Matsushita S**, Funakoshi T, Yamamoto Y, Inozume T, Kishi A, Takenouchi T, Kokubu H, Ito S, Umeda Y, Yamamoto Y, Ishizuki S, Iino S, Uchi H, Nakagawa T, Inafuku K, Haga T, Kaneko T, Nakagawa M, Kamiya H, Arima M, Hoashi T, Hiura A, Kanazawa N, Manabe K, Ishikawa M, Asagoe K, Iwasawa U, Kadono T, Hatta N, Minami S, Nakano E, Ogata D, Fukushima S, Uhara H, Nakama K, Komori T, Igawa K, Nakamura Y.

Prognostic outcomes of immediate complete lymph node dissection versus observation in patients with acral melanoma of the sole with sentinel node metastasis: a retrospective, multicenter study.

Int J Clin Oncol. 2026 Jan; 31(1): 214-222.

Journal Impact Factor 2025: 3.0

PMID: [41345808](https://pubmed.ncbi.nlm.nih.gov/41345808/) doi: [10.1007/s10147-025-02936-6](https://doi.org/10.1007/s10147-025-02936-6)

有効再開通後の 24 時間以降の中期的収縮期血圧変動は転帰不良と関連する

Hamada Y, Matsuoka H, Sato T, Hamada K, Shimada T, Kawabata Y, Iwamoto K, Ikeda M, Takaguchi G, Higuchi Y, Takashima H.

Mid-term systolic BP variability beyond 24 h after successful recanalization predicts poor outcomes following ischemic stroke.

Hypertens Res. 2026 Mar 13. (Online ahead of print)

Journal Impact Factor 2025: 4.6

PMID: [41826505](#) doi: [10.1038/s41440-026-02608-6](#)

2 型糖尿病および糖尿病性腎症患者における腎機能低下とその減速を予測するバイオマーカーの同定

Nishimura M, Yonezawa K, Sawamura M, Tanaka T, Yamamoto Y, Taki H, Hatao M, Takeda M, Hida K, Koide J, Saito M, **Koriyama N**, Watanabe T, Nakajima R, Hoshiyama Y.

Identification of biomarkers to predict renal function decline and its deceleration in patients with type 2 diabetes and diabetic kidney disease.

J Diabetes Complications. 2026 Jan; 40(1): 109208.

Journal Impact Factor 2025: 3.1

PMID: [41197455](#) doi: [10.1016/j.jdiacomp.2025.109208](#).

高齢化社会における皮膚有棘細胞癌に対する免疫療法：免疫老化と老年腫瘍学の視点の統合

Matsushita S, Fujii K, Aoki M.

Immunotherapy for Cutaneous Squamous Cell Carcinoma in Aging Societies: Integrating Immunosenescence and Geriatric Oncology Perspectives.

Cancers. 2026 Feb 26; 18(5): 749.

Journal Impact Factor 2025: 4.4

DOI: [10.3390/cancers18050749](#)

標準治療に抵抗性のある進行性皮膚悪性腫瘍の日本人患者 175 名における包括的ゲノムプロファイリングの臨床的有用性

Kambayashi Y, Fujimura T, Kato H, Kado S, Maekawa T, Ono F, Ito T, **Aoki M**, **Matsushita S**, Miyashita A, Fukushima S, Rokunohe D, Yamazaki E, Takahashi-Watanabe M, Asano M, Asano Y.

Clinical utility of comprehensive genomic profiling in 175 Japanese patients with advanced skin malignancies refractory to standard therapies.

JAAD International. 2026 Apr ; 25: 107-109

Journal Impact Factor 2025: 5.2

DOI: [10.1016/j.jdin.2026.01.012](https://doi.org/10.1016/j.jdin.2026.01.012)

「HDL-C 低値は、急性期脳出血における血腫拡大と関連する：高血圧性微小血管障害との関連」に対する論評への回答

Sato T, Tsuchimochi Y, Hamada Y, Kukihara K, Kawabata Y, Iwamoto K, Takaguchi G, Higuchi Y, Matsuoka H, Takashima H.

Reply to Comment on "Lower high-density lipoprotein cholesterol level is associated with hematoma expansion in acute intracerebral hemorrhage: association with hypertensive microangiopathy".

Hypertens Res. 2026 Feb 27. (Online ahead of print)

Journal Impact Factor 2025: 4.6

PMID: [41760898](https://pubmed.ncbi.nlm.nih.gov/41760898/) DOI: [10.1038/s41440-026-02599-4](https://doi.org/10.1038/s41440-026-02599-4)

「重度の脳小血管病変負荷は脳内出血の脳室内進展と関連する」に対する論評への回答

Sato T, Tsuchimochi Y, Hamada Y, Kukihara K, Kawabata Y, Iwamoto K, Takaguchi G, Higuchi Y, Matsuoka H, Takashima H.

Reply to Critique on "Severe cerebral small vessel disease burden is associated with intraventricular extension of intracerebral hemorrhage".

J Neurol Sci. 2026 Jan 15; 480:125713.

Journal Impact Factor 2025: 3.2

PMID: [41483992](https://pubmed.ncbi.nlm.nih.gov/41483992/) DOI: [10.1016/j.jns.2025.125713](https://doi.org/10.1016/j.jns.2025.125713)

Fibrosis-4 index と予後および血腫量：脳葉型および非脳葉型脳内出血との関連

Sato T, Tsuchimochi Y, Hamada Y, Kukihara K, Kawabata Y, Iwamoto K, Takaguchi G, Higuchi Y, Matsuoka H, Takashima H.

Fibrosis-4 index and prognosis and hematoma volume: association with lobar and non-lobar intracerebral hemorrhage.

Hypertens Res. 2025 Dec 10. (Epub ahead of print)

Journal Impact Factor 2025: 4.6

PMID: [41372675](https://pubmed.ncbi.nlm.nih.gov/41372675/) DOI: [10.1038/s41440-025-02487-3](https://doi.org/10.1038/s41440-025-02487-3)

重度の脳小血管病変負荷は脳内出血の脳室内進展と関連する

Sato T, Tsuchimochi Y, Hamada Y, Kukihara K, Kawabata Y, Iwamoto K, Takaguchi G, Higuchi Y, Matsuoka H, Takashima H.

Severe cerebral small vessel disease burden is associated with intraventricular extension of intracerebral hemorrhage.

J Neurol Sci. 2026 Jan 15; 480:125680.

Journal Impact Factor 2025: 3.2

PMID: [41349495](#) DOI: [10.1016/j.jns.2025.125680](#)

日本人患者の黒色腫のゲノム解析およびトランスクリプトーム解析による免疫チェックポイント阻害剤レスポンドーの候補バイオマーカー明確化

Kimura T, Tanaka N, Maekawa T, Kiniwa Y, Okuyama R, Asai J, Matsushita S, Uchi H, Kato H, Nagase K, Kobayashi A, Tanemura A, Fujimura T, Fujisawa Y, Kunimoto K, Ito T, Mori S, Yoshino K, Yamazaki N, Yano H, Komohara Y, Noda T, Kiyotani K, Mori S, Fukushima S.

Genomic and transcriptomic analyses of melanoma in Japanese patients reveal candidate biomarkers for immune checkpoint inhibitor responders.

Commun Med (Lond). 2026 Jan 7. (Online ahead of print)

Journal Impact Factor 2024: 6.3

PMID : [41501359](#) DOI: [10.1038/s43856-025-01341-4](#)

切除不能悪性黒色腫の治療における TM5614 とニボルマブの併用療法の安全性と有効性を検討する第 III 相試験 : プロトコル

Fujimura T, Yoshino K, Kato H, Fukushima S, Fujisawa Y, Matsushita S, Uhara H, Rokunohe D, Takenouchi T, Maekawa T, Nakamura Y, Namikawa K, Takahashi A, Yoshikawa S, Iwata H, Yamasaki O, Uchi H, Ohno F, Ito T, Tanemura A, Ohe S, Yamazaki E, Takahashi-Watanabe M, Muto Y, Kambayashi Y, Hashimoto A, Asano Y.

Phase III Study Investigating the Safety and Efficacy of TM5614 in Combination With Nivolumab for the Treatment of Unresectable Malignant Melanoma: Protocol.

Exp Dermatol. 2026 Jan;35(1): e70202

Journal Impact Factor 2024: 3.1

PMID : [41504650](#) DOI: [10.1111/exd.70202](#)

切除された爪メラノーマに対する抗 *PD-1* 抗体補助療法と経過観察の有効性

Komori T, Nakano E, Kiniwa Y, Mori S, Yamamoto S, Kato H, Yoshikawa S, Yoshino K, **Aoki M**, Takenouchi T, Maeda T, Yoshino K, Ohe S, Nakama K, Ishikawa H, Nakamura Y, Takai T, Ito T, Kitagawa H, Kokubu H, Hatta N, Funakoshi T, Hoashi T, Suyama T, Fujiwara S, Masuzawa M, Uchi H, Miyagawa T, Kado S, Yamamoto Y, Asai J, Kato J, Maeda T, Baba N, Kato Y, Oashi K, Maekawa T, Jinnai S, Nishizawa A, Kagoyama K, Otsuka A, Nishihara K, Ogata D, Namikawa K, Nakamura Y, **Matsushita S**.

Efficacy of adjuvant anti-*PD-1* antibody versus observation for resected nail apparatus melanoma.

J Eur Acad Dermatol Venereol. 2026 Jan 5

Journal Impact Factor 2024: 8.0

PMID : [41487048](https://pubmed.ncbi.nlm.nih.gov/41487048/) DOI: [10.1111/jdv.70295](https://doi.org/10.1111/jdv.70295)